Opus Point Partners Management’s Ligand Pharmaceuticals LGND Stock Holding History

Opus Point Partners Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$242K	Buy	3,892 +508	+15%	+$31.9K	0.44%	49
2019 Q2	$241K	Buy	3,384 +587	+21%	+$43.2K	0.36%	60
2019 Q1	$219K	Buy	+2,797	New	+$212K	0.3%	72
2017 Q4	–	Sell	-2,435	Closed	-$207K	–	66
2017 Q3	$207K	Sell	2,435 -952	-28%	-$75.4K	0.19%	60
2017 Q2	$257K	Sell	3,387 -2,575	-43%	-$180K	0.24%	56
2017 Q1	$394K	Buy	5,962 +1,812	+44%	+$119K	0.29%	52
2016 Q4	$263K	Buy	+4,150	New	+$262K	0.21%	45

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Opus Point Partners Management's LGND Position: Q3 2019 in Review

Opus Point Partners Management increased its Ligand Pharmaceuticals (LGND) stake by 15% in Q3 2019, buying an estimated $31.9K and bringing the position to 3,892 shares worth $242K. The position accounts for 0.44% of the portfolio, ranked #49.

Opus Point Partners Management first reported a position in LGND in Q4 2016 and has held it in 7 quarters since. The position peaked at $394K in Q1 2017. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

Opus Point Partners Management held 3,892 shares of Ligand Pharmaceuticals worth $242K as of Q3 2019.
Opus Point Partners Management bought 508 Ligand Pharmaceuticals shares in Q3 2019, an estimated $31.9K.
Ligand Pharmaceuticals made up 0.44% of Opus Point Partners Management's portfolio in Q3 2019, its #49 holding.
Opus Point Partners Management first reported a position in Ligand Pharmaceuticals in Q4 2016 and has held it in 7 quarters since.
Opus Point Partners Management's Ligand Pharmaceuticals position peaked at $394K in Q1 2017.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.